학술논문
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
Document Type
article
Author
Naoto Katakami; Tomoya Mita; Hidenori Yoshii; Toshihiko Shiraiwa; Tetsuyuki Yasuda; Yosuke Okada; Akira Kurozumi; Masahiro Hatazaki; Hideaki Kaneto; Takeshi Osonoi; Tsunehiko Yamamoto; Nobuichi Kuribayashi; Kazuhisa Maeda; Hiroki Yokoyama; Keisuke Kosugi; Kentaro Ohtoshi; Isao Hayashi; Satoru Sumitani; Mamiko Tsugawa; Kayoko Ryomoto; Ken Kato; Tadashi Nakamura; Satoshi Kawashima; Yasunori Sato; Hirotaka Watada; Iichiro Shimomura; the UTOPIA study investigators
Source
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-15 (2023)
Subject
Language
English
ISSN
1475-2840
Abstract
Abstract Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of cardiovascular disease. Methods This was a prospective observational 2-year extension study of the “Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)” trial, a 2-year randomized intervention study. The primary endpoints represented changes in the carotid intima-media thickness (IMT). Secondary endpoints included brachial-ankle pulse wave velocity (baPWV) and biomarkers for glucose metabolism, lipid metabolism, renal function, and cardiovascular risks. Results The mean IMT of the common carotid artery (IMT-CCA) significantly decreased in both the tofogliflozin (− 0.067 mm, standard error 0.009, p